Sökning: WFRF:(Bassirian Shirin) > (2019) > MRI Assessment of T...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05271naa a2200529 4500 | |
001 | oai:DiVA.org:liu-162060 | |
003 | SwePub | |
008 | 191119s2019 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1620602 URI |
024 | 7 | a https://doi.org/10.1002/hep.306742 DOI |
040 | a (SwePub)liu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Ajmera, Veeral H.u Univ Calif San Diego Hlth, CA USA4 aut |
245 | 1 0 | a MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial) |
264 | c 2019-06-18 | |
264 | 1 | b WILEY,c 2019 |
338 | a print2 rdacarrier | |
500 | a Funding Agencies|the John A. Hartford Foundation; GALMED; American Association for the Study of Liver Diseases Foundation Clinical and Translational Research Award; Atlantic Philanthropies, Inc. | |
520 | a Aramchol, an oral stearoyl-coenzyme-A-desaturase-1 inhibitor, has been shown to reduce hepatic fat content in patients with primary nonalcoholic fatty liver disease (NAFLD); however, its effect in patients with human immunodeficiency virus (HIV)-associated NAFLD is unknown. The aramchol for HIV-associated NAFLD and lipodystrophy (ARRIVE) trial was a double-blind, randomized, investigator-initiated, placebo-controlled trial to test the efficacy of 12 weeks of treatment with aramchol versus placebo in HIV-associated NAFLD. Fifty patients with HIV-associated NAFLD, defined by magnetic resonance imaging (MRI)-proton density fat fraction (PDFF) amp;gt;= 5%, were randomized to receive either aramchol 600 mg daily (n = 25) or placebo (n = 25) for 12 weeks. The primary endpoint was a change in hepatic fat as measured by MRI-PDFF in colocalized regions of interest. Secondary endpoints included changes in liver stiffness using magnetic resonance elastography (MRE) and vibration-controlled transient elastography (VCTE), and exploratory endpoints included changes in total-body fat and muscle depots on dual-energy X-ray absorptiometry (DXA), whole-body MRI, and cardiac MRI. The mean (+/- standard deviation) of age and body mass index were 48.2 +/- 10.3 years and 30.7 +/- 4.6 kg/m(2), respectively. There was no difference in the reduction in mean MRI-PDFF between the aramchol group at -1.3% (baseline MRI-PDFF 15.6% versus end-of-treatment MRI-PDFF 14.4%, P = 0.24) and the placebo group at -1.4% (baseline MRI-PDFF 13.3% versus end-of-treatment MRI-PDFF 11.9%, P = 0.26). There was no difference in the relative decline in mean MRI-PDFF between the aramchol and placebo groups (6.8% versus 1.1%, P = 0.68). There were no differences in MRE-derived and VCTE-derived liver stiffness and whole-body (fat and muscle) composition analysis by MRI or DXA. Compared to baseline, end-of-treatment aminotransferases were lower in the aramchol group but not in the placebo arm. There were no significant adverse events. Conclusion: Aramchol, over a 12-week period, did not reduce hepatic fat or change body fat and muscle composition by using MRI-based assessment in patients with HIV-associated NAFLD (clinicaltrials.gov ID:NCT02684591). | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Gastroenterologi0 (SwePub)302132 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Gastroenterology and Hepatology0 (SwePub)302132 hsv//eng |
700 | 1 | a Cachay, Edwardu Univ Calif San Diego, CA 92103 USA4 aut |
700 | 1 | a Ramers, Christianu Family Hlth Ctr, CA USA4 aut |
700 | 1 | a Vodkin, Irineu Univ Calif San Diego Hlth, CA USA4 aut |
700 | 1 | a Bassirian, Shirinu Univ Calif San Diego Hlth, CA USA4 aut |
700 | 1 | a Singh, Seemau Univ Calif San Diego Hlth, CA USA4 aut |
700 | 1 | a Mangla, Neeraju Univ Calif San Diego Hlth, CA USA4 aut |
700 | 1 | a Bettencourt, Richeleu Univ Calif San Diego Hlth, CA USA4 aut |
700 | 1 | a Aldous, Jeannette L.u San Ysidro Hlth, CA USA4 aut |
700 | 1 | a Park, Danielu San Ysidro Hlth, CA USA4 aut |
700 | 1 | a Lee, Danielu Univ Calif San Diego, CA 92103 USA4 aut |
700 | 1 | a Blanchard, Jenniferu Univ Calif San Diego, CA 92103 USA4 aut |
700 | 1 | a Mamidipalli, Adrijau Univ Calif San Diego, CA 92093 USA4 aut |
700 | 1 | a Boehringer, Andrewu Univ Calif San Diego, CA 92093 USA4 aut |
700 | 1 | a Aslam, Saimau Univ Calif San Diego, CA 92103 USA4 aut |
700 | 1 | a Dahlqvist Leinhard, Olof,d 1978-u Linköpings universitet,Avdelningen för radiologiska vetenskaper,Medicinska fakulteten,Region Östergötland, Radiofysikavdelningen US,AMRA Med AB, Linkoping, Sweden4 aut0 (Swepub:liu)oloda24 |
700 | 1 | a Richards, Lisau Univ Calif San Diego Hlth, CA USA4 aut |
700 | 1 | a Sirlin, Claude B.u Univ Calif San Diego, CA 92093 USA4 aut |
700 | 1 | a Loomba, Rohitu Univ Calif San Diego, CA 92093 USA4 aut |
710 | 2 | a Univ Calif San Diego Hlth, CA USAb Univ Calif San Diego, CA 92103 USA4 org |
773 | 0 | t Hepatologyd : WILEYg 70:5, s. 1531-1545q 70:5<1531-1545x 0270-9139x 1527-3350 |
856 | 4 | u https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164416 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-162060 |
856 | 4 8 | u https://doi.org/10.1002/hep.30674 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.